In particular, 82% of AML patients exhibited positivity for CRT expression prior to treatment and a similar pattern was observed also for HSP exposure and HMGB1 release, thus suggesting that DAMP production may represent an intrinsic feature of some types of AML, which make them more prone to interact with the immune system. This evidence concerns the gene HMGB1 and acute myeloid leukemia.